Beware of ongoing fraud campaigns to steal your login details or access your account. Never share personal information or install any access software. Learn more.

Pharma Opportunity Certificate

2020 will go down in history as the year of Covid-19. What initially seemed to be a small epidemic limited to China, has spread out to the entire globe, seriously affecting societies and economies while setting off crisis on all imaginable levels. Get involved in the combat against the Coronavirus and invest in companies that are seeking solutions to put an end to this pandemic.

Tubes for chemistery

Pharma Opportunity

ISIN: CH0521605003

There has been an unprecedented eruption of global pharmaceutical research and development related to COVID-19. More than 330 clinical studies and 80 vaccine candidates are currently under review. Big pharma and biotech companies are working to find a drug to manage or defeat COVID-19. With the Pharma Opportunity Certificate, you invest in the performance of companies that are actively working on medicines to combat the coronavirus by developing vaccines or treatments.


 

Benefits

Investing made simple

Looking to invest in a sector you care about, but don’t have the time, knowledge or funds to build and maintain a full portfolio?

Trade a balanced selection of stocks in a single click with Swissquote Themes Trading Certificates. Based on a portfolio of stocks tied to a specific theme or industry sector, they are handpicked and constantly optimized by our experts.

Want to get ahead of the curve?

Subscribe to our Newsletter to receive market news, trade ideas & new themes

Follow us
Be in the know

Sign up to our newsletter and receive a monthly selection right in your inbox


Sponsors
UEFA Europa LeagueGenève ServetteZSC Lions

General Information
This website is operated jointly by Swissquote MEA Ltd. (“SQMEA”) and Swissquote Bank SA’s Representative Office in Dubai (the “Swissquote Representative Office”).
SQMEA is incorporated in the Dubai International Financial Centre (“DIFC”) and regulated by the Dubai Financial Services Authority (“DFSA”).
The Swissquote Representative Office is licensed by the Central Bank of the United Arab Emirates to carry out representative office activities only.
Swissquote Bank SA (“SQB”) is incorporated in Switzerland and regulated by the Swiss Financial Market Supervisory Authority (FINMA).
 
Depending on the section of the website, products and services presented may be promoted by SQMEA or by the Swissquote Representative Office. In particular,
SQMEA does not promote, arrange or offer to Retail Clients access to any services relating to contracts for differences (CFDs), rolling spot foreign exchange, or other Restricted Speculative Investments, as defined in the DFSA Rulebook (www.dfsa.ae).
 
The Swissquote Representative Office promotes CFDs and forex products and supports with the access to Forex & CFDs Accounts.
 
SQMEA operates multiple business lines.
For the target audience of this website, all products and services presented are offered by SQB.
 
No Offer or Advice
The content of this website is provided for information purposes only and does not constitute investment advice, a recommendation, a solicitation, or an offer to buy or sell any financial instruments.
Nothing on this website should be relied upon as the sole basis for making investment decisions. Visitors should seek independent financial, legal, and tax advice before making any investment.
 
Product Availability and Eligibility
Access to products and services described on this website is subject to applicable laws, regulations, and eligibility requirements.
Certain products or services may not be available in all jurisdictions or to all clients, and additional conditions or restrictions may apply.
 
Risk Warning
Investing in financial instruments involves risk, including the possible loss of capital. Past performance is not a reliable indicator of future results.
Further information is available in the “Risks Involved in Trading Financial Instruments” disclosure.
 
AI-Generated Content
Some visual or editorial content on this website may be generated or enhanced using artificial intelligence (AI) tools.
All such content is subject to human review and approval to ensure accuracy, appropriateness, and compliance with applicable regulatory requirements. AI is not used to provide personalised investment advice, suitability assessments, or client-specific recommendations.